News

Sarepta stock plummeted Monday after the company said a second patient died following treatment with its gene therapy, ...
Supernus Pharmaceuticals said it is acquiring Sage Therapeutics, the distressed maker of a drug for postpartum depression, ...
Another person treated with Elevidys suffered acute liver failure, leading Sarepta to discontinue treatment in certain patients while it evaluates new safety precautions.
Cambridge-based Sarepta Therapeutics said it was halting shipments of its Duchenne muscular dystrophy gene therapy for ...
BMO Capital and Piper Sandler downgraded Sarepta Therapeutics (NASDAQ:SRPT) after the company reported a second death linked to its gene therapy Elevidys in a non-ambulatory Duchenne muscular ...
Investing.com -- BMO Capital and Piper Sandler downgraded Sarepta Therapeutics (NASDAQ: SRPT) after the company reported a second death linked to its gene therapy Elevidys in a non-ambulatory Duchenne ...
Sarepta Therapeutics Inc. plummeted in early trading after reporting a second patient died of acute liver failure while being ...
Sarepta Therapeutics ( NASDAQ: SRPT) fell ~38% in the premarket on Monday after the company reported a second fatality from ...
U.S. stock futures point higher, Victoria's Secret shares rise on a report that an activist investor is building a stake in the lingerie company, and EchoStar stock jumps on a report that President ...
Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.
Sarepta’s shares crashed 41% in pre-market trading Monday morning to $21.01 after the biotech reported a second death from ...